Investigational ALS Drug Prolongs Patient Survival in Clinical Trial
An experimental medication that was recently shown to slow the progression of the neurodegenerative disease amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, has now demonstrated the potential to also prolong patient survival.
A Tribute to Sean M. Healey
Two years ago, Sean M. Healey became a part of the Mass General ALS family and an advocate for those with ALS. We are saddened to share the news that Sean M. Healey, our treasured partner, patient and friend passed away peacefully May 26, 2020 with his loving family by his side.
Igniting Innovation Through Research & Trials
The Healey Center for ALS unites the world’s leading experts to revolutionize how treatments are developed for people with amyotrophic lateral sclerosis (ALS). We support and accelerate groundbreaking, innovative global clinical trials for all people with ALS.
Merit Cudkowicz, MD, MSc, and Sean M. Healey, Executive Chairman of Affiliated Managers Group, Inc. (AMG), discuss the creation of the Sean M. Healey and AMG Center for ALS at Mass General.
Contact the ALS Multidisciplinary Clinic in the Healey Center for ALS at Mass General to make an appointment with one of our specialists.
Join our quest to discover life-saving therapies for individuals who are affected by ALS.
Borrowing from successes in cancer drug development, Healey Center and NEALS faculty are leading the first ALS Platform Trial.
The ALS Scholars in Therapeutics program engages clinician-scientists and post-doctoral fellows, in their home institution, embarking on their career path to contribute their talents in the field.
The Healey Center awards two annual prizes celebrating ALS innovators: the Healey International Prize for Innovation in ALS Research, and the Gupta Family Endowed Prize for Innovation in ALS Care.